180 Life Sciences Corp (ATNF) concluded trading on Wednesday at a closing price of $6.47, with 89.1 million shares of worth about $576.47 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 238.74% during that period and on October 16, 2024 the price saw a gain of about 325.66%. Currently the company’s common shares owned by public are about 0.53M shares, out of which, 0.52M shares are available for trading.
Stock saw a price change of 372.26% in past 5 days and over the past one month there was a price change of 225.13%. Year-to-date (YTD), ATNF shares are showing a performance of 59.50% which decreased to -34.61% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.16 but also hit the highest price of $11.21 during that period. The average intraday trading volume for 180 Life Sciences Corp shares is 66.55K. The stock is currently trading 256.77% above its 20-day simple moving average (SMA20), while that difference is up 247.31% for SMA50 and it goes to 165.21% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
180 Life Sciences Corp (NASDAQ: ATNF) currently have 0.53M outstanding shares and institutions hold larger chunk of about 1.32% of that.
The stock has a current market capitalization of $3.43M. It has posted earnings per share of -$28.49 in the same period. It has Quick Ratio of 0.58. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ATNF, volatility over the week remained 42.86% while standing at 18.75% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on September 15, 2021 offering a Buy rating for the stock and assigned a target price of $11 to it.
